drugset
drugset / Trial / NCT02639858

Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC

NCT02639858 ↗

Phase 2 Unknown 31 enrolled Samyang Biopharmaceuticals Corporation
NaSingle-groupOpen-labelTreatment

Summary

A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma

Timeline

Start
2015-10
Primary completion
2020-09
Completion
2020-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel-PM Unknown 75 mg/m2 Intravenous

Indications

head and neck squamous cell carcinoma